Shapiro, C. L., Halabi, S., Gibson, G., Weckstein, D. J., Kirshner, J., Sikov, W. M., … Paskett, E. (2008). Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980. JOURNAL OF CLINICAL ONCOLOGY, 26(15).

Shapiro, C. L., S. Halabi, G. Gibson, D. J. Weckstein, J. Kirshner, W. M. Sikov, E. P. Winer, et al. “Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980.” JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).

Shapiro CL, Halabi S, Gibson G, Weckstein DJ, Kirshner J, Sikov WM, et al. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980. JOURNAL OF CLINICAL ONCOLOGY. 2008 May 20;26(15).

Shapiro, C. L., et al. “Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980.” JOURNAL OF CLINICAL ONCOLOGY, vol. 26, no. 15, AMER SOC CLINICAL ONCOLOGY, May 2008.

Shapiro CL, Halabi S, Gibson G, Weckstein DJ, Kirshner J, Sikov WM, Winer EP, Hudis CA, Isaacs C, Weckstein D, Schilsky RL, Paskett E. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2008 May 20;26(15).